Gene therapy has arrived. What’s next?
Tuesday, March 10 | 8 - 11 a.m. ET
Get Your Ticket
LAST CHANCE! Join STAT next Tuesday, Mar. 10, for a discussion on the future of gene therapies. Our reporters will sit down with top executives and policymakers to explore how to bring about the revolution in medicine gene therapies have promised. Sessions include:
Getting value for our innovation dollars
The top Republican on the House Committee on Energy and Commerce, will join STAT for a conversation about how payors and manufacturers in the gene therapy space can move toward value-based care, putting a focus on quality over quantity.
- Rep. Greg Walden (R-Ore.)
- Moderator: Nicholas Florko, Washington correspondent, STAT
How gene therapy took on cancer
Steve Rosenberg pioneered genetically editing white blood cells to kill tumors. He’ll chart this treatment’s long path to market — and offer us a look ahead.
- Steven Rosenberg, M.D., Ph.D., chief, surgery branch, National Cancer Institute
- Moderator: Sharon Begley, senior writer, science and discovery, STAT
When business and science collide
New gene therapies have immense benefits, but they come at high one-time costs. Leaders from the pharmaceutical and insurance industries and the public sector will join us for this session to discuss how to get these breakthroughs to the patients who need them.
- Remy Brim, vice president of regulatory policy and strategy, health and life sciences practice co-lead, BGR Group
- David Lennon, Ph.D., president, AveXis, a Novartis company
- Prem Shah, Pharm.D., executive vice president, specialty pharmacy and PBM product innovation, CVS Health
- Christi Shaw, chief executive officer, Kite
- Moderator: Ed Silverman, Pharmalot columnist, STAT
Coffee and a light breakfast will be provided, and the panels will be followed by a networking reception.
Subscribe to STAT Plus to access this event and, future STAT Plus events like it for free. Or purchase a ticket for $175/person.
Get Your Ticket
Please note that we are closely monitoring the coronavirus outbreak, and will be in touch with all attendees directly if it affects the execution of this event. At this time, we still plan on hosting this event in Washington D.C. next week. Should you decide after purchasing a ticket that you are unable to attend because of the outbreak, there will be no penalty.